
|Articles|May 14, 2014
How BMS is Doing RBM (Risk-Based Monitoring)
Author(s)Guest Blogger
At this year’s Bio IT World Conference, Thomas Verish, Group Director of Data Operations Services at Bristol-Myers Squibb,
Advertisement
At this year’s Bio IT World Conference, Thomas Verish, Group Director of Data Operations Services at Bristol-Myers Squibb, elaborated on BMS’s risk-based monitoring (RBM) pilot, and how they are leveraging data, statistical analysis and personnel to execute RBM.
In this
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
DTP is Scaling Fast, the Safety Infrastructure is Not
2
U.S. Supreme Court Weighs Inducement Liability Beyond FDA Carve-Out Labels
3
AstraZeneca Shares Drop Following Wainua’s Failed Heart Disease Trial
4
FDA Pauses Release of New CRL’s Following Citizen’s Petition
5




